AU2005222909B2 - Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide - Google Patents

Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide Download PDF

Info

Publication number
AU2005222909B2
AU2005222909B2 AU2005222909A AU2005222909A AU2005222909B2 AU 2005222909 B2 AU2005222909 B2 AU 2005222909B2 AU 2005222909 A AU2005222909 A AU 2005222909A AU 2005222909 A AU2005222909 A AU 2005222909A AU 2005222909 B2 AU2005222909 B2 AU 2005222909B2
Authority
AU
Australia
Prior art keywords
hiv
antigen
immunomodulatory oligonucleotide
immunogen
depleted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005222909A
Other languages
English (en)
Other versions
AU2005222909A1 (en
Inventor
Sudhir Agrawal
Richard Bartholomew
Dorothy Bray
Mario Clerici
Ekambar Kandimalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Aceragen Inc
Original Assignee
Immune Response Corp
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp, Idera Pharmaceuticals Inc filed Critical Immune Response Corp
Publication of AU2005222909A1 publication Critical patent/AU2005222909A1/en
Assigned to THE IMMUNE RESPONSE CORPORATION, IDERA PHARMACEUTICALS, INC. reassignment THE IMMUNE RESPONSE CORPORATION Request for Assignment Assignors: HYBRIDON, INC., THE IMMUNE RESPONSE CORPORATION
Application granted granted Critical
Publication of AU2005222909B2 publication Critical patent/AU2005222909B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2005222909A 2004-03-12 2005-03-11 Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide Ceased AU2005222909B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US55287104P 2004-03-12 2004-03-12
US60/552,871 2004-03-12
PCT/US2005/008238 WO2005089231A2 (en) 2004-03-12 2005-03-11 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Publications (2)

Publication Number Publication Date
AU2005222909A1 AU2005222909A1 (en) 2005-09-29
AU2005222909B2 true AU2005222909B2 (en) 2010-03-11

Family

ID=34994209

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005222909A Ceased AU2005222909B2 (en) 2004-03-12 2005-03-11 Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide

Country Status (7)

Country Link
US (1) US20050266015A1 (cg-RX-API-DMAC7.html)
EP (1) EP1729802A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008500963A (cg-RX-API-DMAC7.html)
CN (1) CN101217973A (cg-RX-API-DMAC7.html)
AU (1) AU2005222909B2 (cg-RX-API-DMAC7.html)
CA (1) CA2557443A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005089231A2 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
MX2009003398A (es) 2006-09-27 2009-08-12 Coley Pharm Gmbh Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
HRP20181039T1 (hr) * 2010-05-28 2018-08-24 Zoetis Belgium S.A. Cjepiva koja sadrže kolesterol i cpg kao jedine molekule koje nose adjuvans

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198685A1 (en) * 2003-01-16 2004-10-07 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
OA13246A (en) * 2003-08-28 2007-01-31 Immune Response Corp Inc Immunogenic HIV Compositions and related methods.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198685A1 (en) * 2003-01-16 2004-10-07 Hybridon, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Horner, A.A. The Journal of Immunology, 2001, Vol.167, pages 1584-1591 *
Lisawan, A., Vaccine, 1996, Vol.16, No.213, pages 142-149 *

Also Published As

Publication number Publication date
CA2557443A1 (en) 2005-09-29
AU2005222909A1 (en) 2005-09-29
EP1729802A2 (en) 2006-12-13
JP2008500963A (ja) 2008-01-17
EP1729802A4 (en) 2009-12-16
US20050266015A1 (en) 2005-12-01
WO2005089231A3 (en) 2007-12-06
WO2005089231A2 (en) 2005-09-29
CN101217973A (zh) 2008-07-09

Similar Documents

Publication Publication Date Title
CA2372960C (en) Hiv immunogenic compositions and methods
US6737066B1 (en) HIV immunogenic compositions and methods
Kim et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen
Sjölander et al. Immune responses to ISCOM® formulations in animal and primate models
Borsutzky et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant
Fast et al. Human trials of experimental AIDS vaccines
Kommareddy et al. MF59: A safe and potent adjuvant for human use
Tsuji et al. HIV‐1‐specific cell‐mediated immunity is enhanced by co‐inoculation of TCA3 expression plasmid with DNA vaccine
Newman et al. Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates
US20050266015A1 (en) Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide
US20030044428A1 (en) Method for treating an HIV-infected individual by combining immunization with structured interruption of anti-retroviral treatment
RU2396346C2 (ru) Применение инактивированного цельного вируса совместимого субтипа для получения бесклеточной вакцины и способ лечения вич-инфекции
US20070253979A1 (en) Immunogenic Hiv Compositions and Related Methods
US20080026448A1 (en) Production of HIV
HK1114789A (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
WO2024173143A2 (en) Vaccines incorporating hiv th/ctl epitope peptides to prevent and treat patients with hiv infection and aids
KR20070019635A (ko) 면역원성 hiv 조성물 및 이와 관련된 방법
AU2011310643A1 (en) Vaccine
Rodríguez-Alonso et al. IMS 4112 and VLP of HBV as Th1 Adjuvants for a Recombinant Protein of HIV-1
Poonam Induction of strong cellular immune responses in the gut mucosa against HIV-1 using a combination vaccine of recombinant Clostridium perfringens and HIV-1 virus like particles
ZA200108559B (en) HIV immunogenic compositions and methods.
MXPA01010784A (en) Hiv immunogenic compositions and methods
WO2003082908A2 (en) Use of the p17 protein of hiv in isolated form for the preparation of a medicament for administration to hiv seropositive patients, as well as pharmaceutical compositions comprising said protein

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THE IMMUNE RESPONSE CORPORATION; IDERA PHARMACEUTI

Free format text: FORMER APPLICANT(S): THE IMMUNE RESPONSE CORPORATION; HYBRIDON, INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired